Professor of Medicine, Cardiovascular Division

Daniel Duprez

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 508 Mayo
8508A (Campus Delivery Code)
Minneapolis, MN 55455

Administrative Assistant Name
Roberta Beach

Administrative Email

Additional Locations

M Health Fairview Clinics & Surgery Center

Professor of Medicine, Cardiovascular Division

Donald and Patricia Garofalo Chair, Preventive Cardiology

Professor, Division of Epidemiology and Community Health

Donald and Patricia Garofalo Chair in Preventive Cardiology

Medical School, University Ghent, Belgium

Residency, University Ghent, Belgium

Fellowship, University Hospital Ghent, Belgium

Fellowship, Mayo Clinic, Minneapolis, MN


Daniel Duprez, MD, PhD was born in Belgium and received his MD and PhD degree at the University of Ghent in Belgium. He completed his medicine residency and cardiology fellowship at the University of Ghent, followed by a fellowship at Mayo Clinic, Rochester, MN. He obtained a Hospital Management degree at the Catholic University of Leuven, Belgium. He was Professor Medicine/Cardiology at the University Ghent Belgium. In 2002, he joined the University of Minnesota, where he is tenured Professor of Medicine/Cardiology, holder of the Donald and Patricia Garofalo Chair in Preventive Cardiology at the School of Medicine and Adjunct Professor of Epidemiology and Community Health at the School of Public Health.

My clinic research is focused on early detection and treatment of cardiovascular disease, arterial stiffness/elasticity in health and disease, lipids and novel biomarkers of inflammation and thrombosis in different ethnicities (CARDIA study, MESA study population, HIV population). I have received multiple NIH grants in these domains. I am a clinical trialist and I have studied dozens of new compounds of clinical trials in phase II, III and IV and have served on many study committees regarding design and adjudication events committees of international outcome trials.

I serve at different NIH scientific grant review committees in USA, at different scientific grant committees of several European countries (Belgium, UK, France, Italy, Czech Republic, Poland), South Africa, United Arabic Emirates, Singapore. I have been involved in international education programs with the European Union regarding review and development.

As a clinician, I focus on early detection of cardiovascular disease, lipid abnormalities, hypertension, and prevention of established atherosclerotic cardiovascular disease.

Awards & Recognition

  • Jan-Frans Heymans Prize, period 1986-1987 of the Royal Academy of Medicine of Belgium
  • Prize Foundation Prof. Dr. G. Verdonck 1997-1999 of the Royal Academy of Medicine of Belgium
  • Prize of the Foundation Dr Karel-Lodewijk Verleysen, period 1998-2001 of the Royal Academy of Medicine of Belgium
  • American Heart Association Hero Award (research category), (2014)
  • Midwest Lipid Association Award in recognition of the outstanding contribution to the Midwest Lipid Association as a Member of the Board of Directors (2013-2018)

Professional Associations

  • Fellow of the American Heart Association
  • Fellow of the American College of Cardiology
  • Fellow of the European Society of Cardiology
  • Fellow of the American Society of Hypertension
  • Fellow of the National Lipid Association
  • Fellow of the American Society of Preventive Cardiology
  • Past-USA governor of the International Society of Cardiovascular Pharmacotherapy
  • Past-President of the National Lipid Association Midwest Chapter
  • Past-President of the European Working Group of Vascular Disease
  • Member of the Board of Directors of the National Lipid Association


Research Summary/Interests

  • Mathematical modeling of the arterial system, arterial stiffness, diagnostic and predictive value in clinical setting and epidemiological study cohorts (MESA study cohort- NIH grants)
  • Role of ethnicity on the predictive value of phenotypes of cardiovascular structure and function, biomarkers of inflammation, coagulation, lipoprotein particles and cardiovascular outcome (MESA study and CARDIA study – NIH grants)
  • Lipoproteins, arterial stiffness, inflammatory markers in HIV patients and target organ damage and outcome (SMART and START – NIH grants)
  • Clinical mechanistic, pharmacodynamics and outcome studies with new therapeutic compounds in the area of hypercholesterolemia/hypertriglyceridemia, hypertension, primary and secondary cardiovascular prevention (phase II, III, IV)
  • Predictive value of cardiovascular biostatistical vs phenotype parameters in the Rasmussen Center for Cardiovascular Disease Prevention (philanthropy)


  • Duprez DA, Duval S, Hoke L, Florea N, Grandits G, Carlson C, Lee J, Cohn JN. Early cardiovascular structural and functional abnormalities as a guide to future morbid events. Eur J Prev Cardiol. 2020 Feb 4:2047487320901416. doi: 10.1177.
  • Duprez DA, Gross MD, Ix JH, Peralta CA, Kizer JR, Shea S, Jacobs DR Jr. Collagen biomarkers are associated with decline in renal function independently of blood pressure and other cardiovascular risk factors: the Multi-Ethnic Study of Atherosclerosis Study. J Hypertens. 2019;37(12):2398-2403. doi: 10.1097.
  • Duprez DA, Forbang NI, Allison MA, Peralta CA, Shea S, Jacobs DR Jr. Association of C2, a derivative of the radial artery pressure waveform, with new onset of type 2 diabetes mellitus: the MESA study. Cardiovasc Diabetol. 2019;18(1):62. doi: 10.1186.
  • Duprez DA, Gross MD, Kizer JR, Ix JH, Hundley WG, Jacobs DR Jr. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018;7(5):e007885. doi: 10.1161
  • Duprez DA, Gross MD, Sanchez OA, Kizer JR, Ix JH, Lima J, Tracy RP, Jacobs DR Jr. Collagen Turnover Markers in Relation to Future Cardiovascular and Noncardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2017;63(7):1237-1247. doi: 10.1373.


Teaching Areas

Academic Interest and Focus

Lipid abnormalities, Arterial Mechanics, Arterial stiffness, Ventriculo-vascular coupling, Structural and functional cardiovascular abnormalities, study cohorts, clinical trials and design (Phase II, III, IV), Cardiovascular Disease, Epidemiology and Public Health